Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Linjie Ruan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0003-1220-2371; OpenAlex author ID A5091127801. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2023: 1 paper · 2024: 3 papers · 2025: 3 papers · 2026: 1 paper

Papers 8

  1. Luteolin Triggers Pyroptosis in Pancreatic Ductal Adenocarcinoma by Inhibiting Mitochondrial Fission through the RAS/ERK/DRP1 Pathway. Co-author DOI 10.1142/s0192415x26500606↗
  2. Alpha-Heredin targets CAMKⅡ/DRP1-Mediated mitochondrial fission to trigger ferroptosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.phymed.2025.157048↗
  3. Modified Sijunzi Decoction Inhibits Pancreatic Cancer Progression and Improves Immune Suppression: Network Pharmacology and Experimental Validation. First author DOI 10.2147/dddt.s520390↗
  4. Identification of Syndrome Types in Patients With Pancreatic Cancer From Free Text in Electronic Medical Records: Model Development and Validation. Co-author DOI 10.2196/70602↗
  5. Berberine chloride suppresses pancreatic adenocarcinoma proliferation and growth by targeting inflammation-related genes: an in silico analysis with in vitro a… Co-author DOI 10.1007/s00280-024-04663-7↗
  6. KIF20B and MET, hub genes of DIAPHs, predict poor prognosis and promote pancreatic cancer progression. Co-author DOI 10.1016/j.prp.2023.155046↗
  7. EIF2Ss, a Novel c-Myc-Correlated Gene Family, is Associated with Poor Prognosis and Immune Infiltration in Pancreatic Adenocarcinoma. Co-author DOI 10.31083/j.fbl2903119↗
  8. Paired protein kinases PRKCI-RIPK2 promote pancreatic cancer growth and metastasis via enhancing NF-κB/JNK/ERK phosphorylation. First author DOI 10.1186/s10020-023-00648-z↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhen Chen · 6 shared papers, 2023–2026 · strength 1.54
  2. He Ba · 5 shared papers, 2024–2026 · strength 1.41
  3. Chien‐shan Cheng · 5 shared papers, 2023–2025 · strength 1.20
  4. Yuan Zhang · 4 shared papers, 2025–2026 · strength 1.17
  5. Peiwen Yang · 4 shared papers, 2023–2026 · strength 1.09
  6. Juying Jiao · 4 shared papers, 2023–2024 · strength 0.89
  7. Waimei Si · 3 shared papers, 2025–2026 · strength 0.87
  8. Xin Li · 3 shared papers, 2025–2026 · strength 0.87
  9. Zhangqi Cao · 3 shared papers, 2024 · strength 0.68
  10. Fengjiao Wang · 3 shared papers, 2023–2024 · strength 0.65
  11. Yanhua Jing · 2 shared papers, 2024 · strength 0.43
  12. Ke Zhang · 2 shared papers, 2024 · strength 0.43
  13. Lixia Yi · 1 shared paper, 2026 · strength 0.30
  14. Zhen Chen · 1 shared paper, 2025 · strength 0.28
  15. Zhen Chen · 1 shared paper, 2024 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.